| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9907751 | ROMEG | Composition and method of use of colchicine oral liquid |
Nov, 2036
(13 years from now) | |
| US10383820 | ROMEG | Colchicine drug-to-drug interactions |
Nov, 2036
(13 years from now) | |
| US10383821 | ROMEG | Colchicine drug-to-drug interactions |
Nov, 2036
(13 years from now) | |
| US10226423 | ROMEG | Colchicine drug-to-drug interactions |
Dec, 2037
(14 years from now) | |
Gloperba is owned by Romeg.
Gloperba contains Colchicine.
Gloperba has a total of 4 drug patents out of which 0 drug patents have expired.
Gloperba was authorised for market use on 30 January, 2019.
Gloperba is available in solution;oral dosage forms.
Gloperba can be used as a method of prophylactic treatment of gout flares in adults comprises administering to a patient a liquid colchicine oral solution.
The generics of Gloperba are possible to be released after 20 December, 2037.
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 30 January, 2019
Treatment: A method of prophylactic treatment of gout flares in adults comprises administering to a patient a liquid colchicine oral solution
Dosage: SOLUTION;ORAL
GLOPERBA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic